Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms
نویسندگان
چکیده
منابع مشابه
PANCREATIC NEUROENDOCRINE NEOPLASMS (pNENs)
Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare lesions that have been increasing in incidence over the past few decades largely because of the diagnosis of pancreatic incidentalomas on cross-sectional imaging. Most of these tumors are nonfunctioning presenting with symptoms secondary to mass effect, metastatic disease or as incidental findings. Diagnostic workup aims to assess ...
متن کاملPancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms)
INTRODUCTION Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare tumors representing 1% to 2% of all pancreatic neoplasms. These tumors can secrete a variety of biologically active substances giving rise to distinct clinical symptoms or can be clinically nonfunctioning. Apart from insulinomas and gastrinomas, which constitute the majority of functioning pNENs, some tumors may secret...
متن کاملOutcome of surgery for pancreatic neuroendocrine neoplasms.
BACKGROUND The incidence of pancreatic neuroendocrine neoplasms (pNEN) is increasing. This study aimed to evaluate predictors of overall survival and the indication for surgery. METHODS Data collected between October 2001 and December 2012 were analysed. Histological grading and staging was based on the classifications of the World Health Organization, the International Union Against Cancer a...
متن کاملTreatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
Pancreatic neuroendocrine tumors (PanNETs) are frequently diagnosed at unresectable stage and remain a medical challenge. Everolimus (RAD001, Afinitor(®), Novartis, Basel, Switzerland), an orally administered inhibitor of mammalian target of rapamycin (mTOR), was recently approved by the Food and Drug Administration to treat patients with advanced PanNETs. This review will examine the mechanism...
متن کاملEmerging treatment modalities for advanced pancreatic neuroendocrine tumors.
It was with great interest that we read the article titled “Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?” by I. Perysinakis et al published in the first issue of 2016 of the Journal.1 The authors review the recent literature concerning advanced pancreatic neuroendocrine tumors (pNETs) and highlight the fact that there is increasing evidence ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Medicine
سال: 2020
ISSN: 2077-0383
DOI: 10.3390/jcm9061860